Mixed Amphetamine Salts

ApprovedSmall molecule

Mixed Amphetamine Salts is one of 124 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

CognitionActive, not recruiting

Bipolar DisorderActive, not recruiting

Attention Deficit Hyperactivity DisorderApproved

Active, not recruiting

CognitionPhase 1

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

192 competitors in Bipolar Disorder

#DrugCompanyPhaseTrials

Depacon

AbbVie

Phase 3

6 2

Depakote

AbbVie

Phase 3

5 3

Depakote

AbbVie

Phase 3

5 4

Lexapro

AbbVie

Phase 3

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

3 6

Ketalar

Boehringer Ingelheim

Phase 3

2 7

Methylthioninium Chloride

PProvepharm SAS

Phase 3

1 8

Rescue

Merck & Co.

Phase 3

2 9

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Diluent

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder2 trials

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

Completed·—·Phase 4·NCT00889915·228 enrolled

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Completed·SStony Brook University·Phase 4·NCT00228046·40 enrolled

TED1 trial

Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants

Unknown status·UUnited States Army Aeromedical Research Laboratory·Phase 2·NCT03893032·80 enrolled

Children1 trial

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Completed· Takeda logo

Takeda·Phase 4·NCT00506727·215 enrolled

Effectiveness1 trial

Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial

Active, not recruiting·UUniversity of Maryland, College Park·Phase 3·NCT04240756·240 enrolled

Cognition1 trial

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Completed· Takeda logo

Takeda·Phase 1·NCT01010750·18 enrolled

1 more indication

Bipolar Disorder1 trial

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

Completed·UUniversity of Cincinnati·Phase 4·NCT02478788·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Mixed Amphetamine Salts. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mixed Amphetamine Salts compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mixed Amphetamine Salts. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Takeda

Mixed Amphetamine Salts

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder2 trials

TED1 trial

Children1 trial

Effectiveness1 trial

Cognition1 trial

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News